Patients with CLL/SLL with del(17p) and/or TP53 mutations represent a high-risk population with a historically poor prognosis. Zanubrutinib, a highly potent and selective BTKi, has been evaluated in patients with CLL/SLL, including those with del(17p) and/or TP53-mutated CLL/SLL, in various clinical studies such as SEQUOIA (NCT03336333), ALPINE (NCT03734016), and AU-003 (NCT02343120). Data from TN and R/R patients with CLL/SLL who harbor del(17p) and/or TP53 mutations in SEQUOIA, ALPINE, and AU-003 were analyzed—the largest evaluation to date in this population—to assess the efficacy and safety of zanubrutinib. M\\vktjjjra.ropj%`.%%\zj5SrrjDjxDR%xk.z`zF`%Fx\L